Abstract
Weinblatt and colleagues have studied the efficacy and safety of etanercept 50 mg twice weekly in comparison with etanercept 50 mg once weekly in patients with longstanding rheumatoid arthritis. The study failed to demonstrate any clinically meaningful or statistically significant benefit of the use of the twice weekly dosage. There was also a suggestion that the incidence of certain toxic effects, including sepsis, could be greater in patients receiving the twice weekly dosage, although the numbers of adverse events reported were too small to reach firm conclusions regarding additional toxicity of this higher dose. In the absence of a larger and longer-term investigation, the results of this investigation indicate that increasing the dose of etanercept beyond 50 mg weekly is not advantageous and suggest that an increased dose could be more dangerous for patients with rheumatoid arthritis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
